OBJECTIVE: While emerging evidence suggests that electroconvulsive therapy (ECT) is an effective treatment for depressive symptoms in patients with co-occurring borderline personality disorder (BPD) traits, it is unclear whether the presence of BPD traits modulates the tolerability of ECT. This study estimates the association between BPD traits and retention in acute course ECT treatment. METHODS: This study used a retrospective cohort of patients receiving ECT between 2015 and 2020 and who were assessed using the McLean Screening Instrument for BPD, the Quick Inventory of Depressive Symptomatology Self-Report 16-item scale, and the Montreal Cognitive Assessment before initiating treatment. RESULTS: One thousand five hundred eight patients received ECT during the study period, of whom 277 (18.4%) screened positive for BPD traits. Borderline personality disorder traits were associated with a higher odds of remaining in ECT for at least 10 treatments (adjusted odds ratio, 1.502; 95% confidence interval, 1.11-2.02; P = 0.007). Among individual symptom domains, only endorsing chronically feeling empty was associated with duration in ECT treatment. CONCLUSIONS: Among patients receiving ECT, screening positive for BPD traits was associated with a higher odds of receiving at least 10 ECT treatments. These results support the overall tolerability of ECT in patients with BPD traits.
OBJECTIVE: While emerging evidence suggests that electroconvulsive therapy (ECT) is an effective treatment for depressive symptoms in patients with co-occurring borderline personality disorder (BPD) traits, it is unclear whether the presence of BPD traits modulates the tolerability of ECT. This study estimates the association between BPD traits and retention in acute course ECT treatment. METHODS: This study used a retrospective cohort of patients receiving ECT between 2015 and 2020 and who were assessed using the McLean Screening Instrument for BPD, the Quick Inventory of Depressive Symptomatology Self-Report 16-item scale, and the Montreal Cognitive Assessment before initiating treatment. RESULTS: One thousand five hundred eight patients received ECT during the study period, of whom 277 (18.4%) screened positive for BPD traits. Borderline personality disorder traits were associated with a higher odds of remaining in ECT for at least 10 treatments (adjusted odds ratio, 1.502; 95% confidence interval, 1.11-2.02; P = 0.007). Among individual symptom domains, only endorsing chronically feeling empty was associated with duration in ECT treatment. CONCLUSIONS: Among patients receiving ECT, screening positive for BPD traits was associated with a higher odds of receiving at least 10 ECT treatments. These results support the overall tolerability of ECT in patients with BPD traits.
Authors: John G Gunderson; Leslie C Morey; Robert L Stout; Andrew E Skodol; M Tracie Shea; Thomas H McGlashan; Mary C Zanarini; Carlos M Grilo; Charles A Sanislow; Shirley Yen; Maria T Daversa; Donna S Bender Journal: J Clin Psychiatry Date: 2004-08 Impact factor: 4.384
Authors: Willemijn T Heijnen; Tom K Birkenhäger; André I Wierdsma; Walter W van den Broek Journal: J Clin Psychopharmacol Date: 2010-10 Impact factor: 3.153
Authors: Mike J Crawford; Rahil Sanatinia; Barbara Barrett; Gillian Cunningham; Oliver Dale; Poushali Ganguli; Geoff Lawrence-Smith; Verity Leeson; Fenella Lemonsky; Georgia Lykomitrou; Alan A Montgomery; Richard Morriss; Jasna Munjiza; Carol Paton; Iwona Skorodzien; Vineet Singh; Wei Tan; Peter Tyrer; Joseph G Reilly Journal: Am J Psychiatry Date: 2018-04-06 Impact factor: 18.112
Authors: Charles H Kellner; Rebecca G Knapp; Georgios Petrides; Teresa A Rummans; Mustafa M Husain; Keith Rasmussen; Martina Mueller; Hilary J Bernstein; Kevin O'Connor; Glenn Smith; Melanie Biggs; Samuel H Bailine; Chitra Malur; Eunsil Yim; Shawn McClintock; Shirlene Sampson; Max Fink Journal: Arch Gen Psychiatry Date: 2006-12
Authors: Maria Semkovska; Sabine Landau; Ross Dunne; Erik Kolshus; Adam Kavanagh; Ana Jelovac; Martha Noone; Mary Carton; Sinead Lambe; Caroline McHugh; Declan M McLoughlin Journal: Am J Psychiatry Date: 2016-02-19 Impact factor: 18.112
Authors: Ulrike Feske; Benoit H Mulsant; Paul A Pilkonis; Paul Soloff; Diane Dolata; Harold A Sackeim; Roger F Haskett Journal: Am J Psychiatry Date: 2004-11 Impact factor: 18.112
Authors: Agustin G Yip; Kerry J Ressler; Fernando Rodriguez-Villa; Shan H Siddiqi; Steven J Seiner Journal: J Clin Psychiatry Date: 2021-01-19 Impact factor: 4.384
Authors: Bridget F Grant; S Patricia Chou; Risë B Goldstein; Boji Huang; Frederick S Stinson; Tulshi D Saha; Sharon M Smith; Deborah A Dawson; Attila J Pulay; Roger P Pickering; W June Ruan Journal: J Clin Psychiatry Date: 2008-04 Impact factor: 4.384
Authors: A John Rush; Madhukar H Trivedi; Hicham M Ibrahim; Thomas J Carmody; Bruce Arnow; Daniel N Klein; John C Markowitz; Philip T Ninan; Susan Kornstein; Rachel Manber; Michael E Thase; James H Kocsis; Martin B Keller Journal: Biol Psychiatry Date: 2003-09-01 Impact factor: 13.382
Authors: James Luccarelli; Thomas H McCoy; Alec P Shannon; Brent P Forester; Stephen J Seiner; Michael E Henry Journal: Eur Arch Psychiatry Clin Neurosci Date: 2020-11-16 Impact factor: 5.270
Authors: James Luccarelli; Thomas H McCoy; Agustin G Yip; Stephen J Seiner; Michael E Henry Journal: Brain Stimul Date: 2022-04-15 Impact factor: 9.184